Results 21 to 30 of about 72,228 (243)

Molecular dissection of Janus kinases as drug targets for inflammatory diseases

Frontiers in Immunology, 2022
The Janus kinase (JAK) family enzymes are non-receptor tyrosine kinases that phosphorylate cytokine receptors and signal transducer and activator of transcription (STAT) proteins in the JAK-STAT signaling pathway.
Sunghark Kwon
doaj   +1 more source

A multitask GNN-based interpretable model for discovery of selective JAK inhibitors

Journal of Cheminformatics, 2022
The Janus kinase (JAK) family plays a pivotal role in most cytokine-mediated inflammatory and autoimmune responses via JAK/STAT signaling, and administration of JAK inhibitors is a promising therapeutic strategy for several diseases including COVID-19 ...
Yimeng Wang, Yaxin Gu, Chaofeng Lou, Yuning Gong, Zengrui Wu, Weihua Li, Yun Tang, Guixia Liu   +7 more
doaj   +1 more source

JAK Inhibitors — More Than Just Glucocorticoids

New England Journal of Medicine, 2021
Most persons who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are asymptomatic or have only mild-to-moderate symptoms, whereas others have progression to severe di...
Justin Stebbing, Volker M. Lauschke
openaire   +4 more sources

JAK-STAT pathway inhibitors in dermatology

Anais Brasileiros de Dermatologia, 2023
The JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different JAK-STAT signaling patterns have potential indications for various medical conditions.
Hélio Amante Miot, Paulo Ricardo Criado, Caio César Silva de Castro, Mayra Ianhez, Carolina Talhari, Paulo Müller Ramos   +5 more
openaire   +4 more sources

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition

Pharmacology Research & Perspectives, 2019
Janus kinase (JAK) inhibitors have emerged as an effective class of therapies for various inflammatory diseases such as rheumatoid arthritis (RA). JAK inhibitors function intracellularly by modulating the catalytic activity of JAKs and disrupting the ...
Martin E. Dowty, Tsung H. Lin, Michael I. Jesson, Martin Hegen, David A. Martin, Vaibhav Katkade, Sujatha Menon, Jean‐Baptiste Telliez   +7 more
doaj   +1 more source

Targeting the Janus Kinase Family in Autoimmune Skin Diseases

Frontiers in Immunology, 2019
Autoimmune skin diseases are characterized by significant local and systemic inflammation that is largely mediated by the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway.
Michael D. Howell, Fiona I. Kuo, Paul A. Smith   +2 more
doaj   +1 more source

Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis

Frontiers in Pharmacology, 2023
Objectives: This study aimed to evaluate the risk of venous thrombosis (VTE) associated with Janus kinase (JAK) inhibitors in patients diagnosed with immune-mediated inflammatory diseases.Methods: We conducted a comprehensive search of PUBMED, Cochrane ...
Juqi Zhang, Juqi Zhang, Juqi Zhang, Wenhui Li, Wenhui Li, Wenhui Li, Mingli Gong, Yanlun Gu, Yanlun Gu, Yanlun Gu, Hanxu Zhang, Hanxu Zhang, Hanxu Zhang, Bingqi Dong, Qi Guo, Qi Guo, Qi Guo, Xiaocong Pang, Xiaocong Pang, Qian Xiang, Qian Xiang, Xu He, Xu He, Yimin Cui, Yimin Cui, Yimin Cui   +25 more
doaj   +1 more source

Effect of JAK inhibitors on the three forms of bone damage in autoimmune arthritis: joint erosion, periarticular osteopenia, and systemic bone loss

Inflammation and Regeneration, 2023
Background The types of bone damage in rheumatoid arthritis (RA) include joint erosion, periarticular osteoporosis, and systemic osteoporosis. Janus kinase (JAK) inhibitors ameliorate inflammation and joint erosion in RA, but their effect on the three ...
Masatsugu Komagamine, Noriko Komatsu, Rui Ling, Kazuo Okamoto, Shi Tianshu, Kotaro Matsuda, Tsutomu Takeuchi, Yuko Kaneko, Hiroshi Takayanagi   +8 more
doaj   +1 more source

The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies

Frontiers in Pharmacology, 2022
Background: Due to the lack of comprehensive evidence based on prospective studies, the efficacy and safety of Janus Kinase (JAK) inhibitors (including tofacitinib, ruxolitinib, baricitinib, ritlecitinib and brepocitinib) for alopecia areata (AA) are yet
Diqin Yan, Diqin Yan, Huaying Fan, Min Chen, Min Chen, Lin Xia, Lin Xia, Simin Wang, Simin Wang, Wenliang Dong, Wenliang Dong, Qian Wang, Suping Niu, Huiying Rao, Liming Chen, Xiaoyan Nie, Yi Fang   +16 more
doaj   +1 more source

JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases

Frontiers in Medicine, 2023
Inflammatory bowel disease (IBD) is a chronic immune-mediated condition of the gastrointestinal tract that requires chronic treatment and strict surveillance.
Claudia Herrera-deGuise, Xavier Serra-Ruiz, Ernesto Lastiri, Natalia Borruel   +3 more
doaj   +1 more source